Treatment heterogeneity and individual qualitative interaction

American Statistician

Volumn 66, Issue 1, 2012, Pages 16-24

  Poulson, Robert S ^a   Gadbury, Gary L ^b   Allison, David B ^c  

^a AIR FORCE RESEARCH LABORATORY   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Causation; Cross over interaction; Individual effects; Potential outcomes; Probability of similar response; Subject treatment interaction

Indexed keywords

EID: 84862677307     PISSN: 00031305     EISSN: None     Source Type: Journal    
DOI: 10.1080/00031305.2012.671724     Document Type: Article

References (39)

1. 2 Experimental Units," Biometrics, 24, 61-73.
2. Brown, B. W. (1980), "The Crossover Experiment for Clinical Trials," Biometrics, 36, 69-79.
3. Byar, D. P., and Corle, D. K. (1977), "Selecting Optimal Treatment in Clinical Trials Using Covariate Information," Journal of Chronic Diseases, 30, 445-459
4. Darwin, C. (1871), On the Origin of Species (5th ed.), New York: D. Appleton and Company
5. Endrenyi, L., and Tothfalusi, L. (1999), "Subject-by-Formulation Interaction in Determinations of Individual Bioequivalence: Bias and Prevalence," Pharmaceutical Research, 16, 186-190
6. Fan, Y., and Park, S. S. (2009), "Partial Identification of the Distribution of Treatment Effects and its Confidence Sets," in Nonparametric Econometric Methods (Advances in Econometrics, Volume 25), eds. Qi Li and Jeffrey Racine, Bingley, UK: Emerald, pp. 3-70
7. Fan, Y., and Park, S. S. (2010), "Sharp Bounds on the Distribution of Treatment Effects and Their Statistical Inference," Econometric Theory, 26, 931-951
8. Gadbury, G. (2001), "Randomization Inference and Bias of Standard Errors," The American Statistician, 55, 310-313
9. Gadbury, G. (2010), "Subject-Treatment Interaction," in Encyclopedia of Biophar-maceutical Statistics, Third Edition, Revised and Expanded, eds. Shein-Chung Chow, London: Informa Healthcare, pp. 1316-1321
10. Gadbury, G. L., and Iyer, H. K. (2000), "Unit-Treatment Interaction and Its Practical Consequences," Biometrics, 56, 882-885
11. Gadbury, G. L., Iyer, H. K., and Allison, D. B. (2001), "Evaluating Subject-Treatment Interaction When Comparing Two Treatments," Journal of Bio-pharmaceutical Statistics, 11, 313-333
12. Gail, M., and Simon, R. (1985), "Testing for Qualitative Interactions Between Treatment Effects and Patient Subsets," Biometrics, 41, 361-372
13. Gastwirth, J. L. (1975), "Statistical Measures of Earnings Differentials," The American Statistician, 29, 32-35
14. Hauck, W. W., Hyslop, T., Mei-Ling, C., Patnaik, R., and Williams, R. L. (2000), "Subject-by-Formulation Interaction in Bioequivalence: Conceptual and Statistical Issues," Pharmaceutical Research, 17, 375-380
15. Holland, P. W.(1986), "Statistics and Causal Inference," Journal of the American Statistical Association, 81, 945-960
16. Hu, J., Redden, D. T., Berrettini, W. H., Shields, P. G., Restine, S. L., Pinto, A., Lerman, C., and Allison, D. B. (2006), "No Evidence for a Major Role of Polymorphisms During Bupropion Treatment," Obesity (Silver Spring), 14, 1863-1867.
17. Inman, H. F., and Bradley, E. L. (1989), "The Overlapping Coefficient as a Measure of Agreement Between Probability Distributions and Point Estimation of the Overlap of Two Normal Densities," Communications in Statistics: Theory and Methods, 18, 3851-3874.
18. Inoue, J., Hoshino, R., Nojima, H., Ishida, W., and Okamoto, N. (2010), "Investigation of Responders and Non-Responders to Long-Term Donepezil Treatment," Psychogeriatrics, 10(2), 53-61.
19. Li, J., and Chan, I. S. F. (2006), "Detecting Qualitative Interactions in Clinical Trials: An Extension of Range Test," Journal of Biopharmaceutical Statistics, 16, 831-841.
20. Longford, N. T. (1999), "Selection Bias and Treatment Heterogeneity in Clinical Trials," Statistics in Medicine, 18, 1467-1474.
21. Lucretius. "On the Nature of Things," Available at http://classics.mit.edu/Carus/nature_things.4.iv.html.
22. Maki, K. C., Rains, T. M., Kaden, V. N., Raneri, K. R., and Davidson, M. H. (2007), "Effects of a Reduced-Glycemic-Load Diet on Body Weight, Body Composition, and Cardiovascular Disease Risk Markers in Overweight and Obese Adults," American Journal of Clinical Nutrition, 85, 724-734.
23. Marchant, G. E. (2001), "Genetics and Toxic Torts," Seton Hall Law Review, 31, 949.
24. Marchant, G. E. (2010). "Genetics and Toxic Torts," Available at http://www.law.asu.edu/files/Programs/Sci-Tech/Commentaries/Marchant%20Formatted.rev.doc.
25. Marshall, A. (1997), "Laying the Foundations for Personalized Medicines," Nature Biotechnology, 15, 954-957.
26. Mayor, S. (2010), "NICE Recommends Widening Choice of Biological Drugs for Patients With Rheumatoid Arthritis," BMJ, 340, 3477.
27. Peto, R. (1982), Statistical Aspects of Cancer Trials, London: Chapman and Hall.
28. Rom D. M., and Hwang, E. (1996), "Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses," Statistics in Medicine, 15, 1489-1505.
29. Roses, A. D. (2000), "Pharmacokinetics and the Practice of Medicine," Nature, 405, 857-865.
30. Rubin, D. B. (1974), "Estimating Causal Effects for Treatments in Randomized and Nonrandomized Studies," Journal of Educational Psychology, 66, 688-701.
31. Senn, S. (1997), Letter to the Editor on "Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses," Statistics in Medicine, 16, 1301-1306.
32. Senn, S. (2001), "Individual Therapy: New Dawn or False Dawn?" Drug Information Journal, 35, 1479-1494
33. Senn, S. (2006a), "Cross-Over Trials in Statistics in Medicine: The First '25' Years," Statistics in Medicine, 25, 3430-3442
34. Senn, S. (2006b), Letter to the Editor on "Probability Index: An Intuitive Non-Parametric Approach to Measuring the Size of Treatment Effects," Statistics in Medicine, 25, 3944-3948.
35. Silvapulle, M. J. (2001), "Tests for Qualitative Interaction: Exact Critical Values and Robust Tests," Biometrics, 57, 1157-1165.
36. Simon, R. (1982), "Patient Subsets and Variation in Therapeutic Efficacy," British Journal of Pharmacology, 14, 473-482.
37. Smith, C. M. (2005), "Origin and Uses of Primum Non Nocere-Above All, Do No Harm!," Journal of Clinical Pharmacology, 45, 371-377.
38. Stine, R. A., and Heyse, J. F. (2001), "Non-Parametric Estimates of Overlap," Statistics in Medicine, 20, 215-236.
39. Yang, M., and Stufken, J. (2008), "Optimal and Efficient Crossover Designs for Comparing Test Treatments to a Control Treatment Under Various Models," Journal of Statistical Planning and Inference, 138, 278-285.